Ischemic Heart Disease (IHD) Drugs Market 2024 – Growth, Market Size, Analysis, Competitive Landscape | Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG rnell, Johns Hopkins Hospital

The Ischemic Heart Disease (IHD) Drugs Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Ischemic Heart Disease (IHD) Drugs Market:
https://www.thebusinessresearchcompany.com/report/ischemic-heart-disease-ihd-drugs-global-market-report

According to The Business Research Company’s Ischemic Heart Disease (IHD) Drugs Global Market Report 2024, The ischemic heart disease (ihd) drugs market size has grown strongly in recent years. It will grow from $6.02 billion in 2023 to $6.36 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies..

The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.57 billion in 2028 at a compound annual growth rate (CAGR) of 4.4%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations.. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs..

The growing prevalence of obesity and diabetes is expected to propel the growth of the ischemic heart disease (IHD) drugs market going forward. Diabetes is a long-term metabolic disease that causes high blood glucose levels, and obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact health. Ischemic heart disease drugs are often used in individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, mitigating the risk of ischemic heart disease. For instance, in March 2023, according to the World Obesity Federation, a UK-based not-for-profit organization, by 2035, obesity rates are expected to double among boys, reaching 208 million (a 100% increase), and more than double among girls, totaling 175 million (a 125% increase), as reported from 2020 levels. Further, It is estimated that the number of people living with obesity will reach 2.7 billion by 2025. Furthermore, in December 2021, according to the International Diabetes Federation, a US-based intergovernmental organization, diabetes affected 537 million adults (20–79 years old) in 2021, and it is predicted that the number would climb to 643 million people by 2030 and a total of 783 million by 2045. Therefore, the growing prevalence of obesity and diabetes drives the growth of the ischemic heart disease (IHD) drugs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample.aspx?id=13467&type=smp

The ischemic heart disease (ihd) drugs market covered in this report is segmented –
1) Ischemic Heart Disease (IHD) Drugs Market By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) Ischemic Heart Disease (IHD) Drugs Market By Disease Class: Angina Pectoris, Myocardial Infarction
3) Ischemic Heart Disease (IHD) Drugs Market By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Top Major Players

Pfizer Inc.

F. Hoffmann-La Roche Ltd.

Merck & Co. Inc.

AbbVie Inc.

Bayer AG rnell

Johns Hopkins Hospital

Major companies operating in the ischemic heart disease (IHD) drugs market are increasing their focus on developing innovative platelet inhibitors, such as intravenous P2Y12 platelet inhibitors, to gain a competitive edge in the market. An intravenous P2Y12 platelet inhibitor is a medication administered directly into the bloodstream to prevent platelet activation and aggregation and reduce the risk of periprocedural myocardial infarction (MI), an ischemic heart disease. For instance, in October 2021, MSN Laboratories Private Limited, an India-based research-based pharmaceutical company, launched CANREAL injection (Cangrelor), the only intravenous P2Y12 platelet inhibitor with rapid onset and offset of platelet inhibition. It was developed to overcome both delayed and prolonged antiplatelet activity. It is a bioequivalent generic drug that is indicated as an adjunct to percutaneous coronary intervention to reduce the risk of myocardial infarction (MI).

The ischemic heart disease (IHD) drugs market report table of contents includes:

1. Executive Summary

2. Ischemic Heart Disease (IHD) Drugs Market Characteristics

3. Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies

4. Ischemic Heart Disease (IHD) Drugs Market – Macro Economic Scenario

5. Global Ischemic Heart Disease (IHD) Drugs Market Size and Growth

…..

32. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Benchmarking

33. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

35. Ischemic Heart Disease (IHD) Drugs Market Future Outlook and Potential Analysis

36. Appendix